{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-027085","form_type":"8-K","ticker":"LIXT","cik":"0001335105","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2024-07-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.702717+00:00","generated_at":"2026-05-31T20:58:02.722207+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"medium","headline":"Lixte terminates City of Hope trial agreement for LB-100 Phase 1b; seeks new sites","bullets":["Terminated Clinical Research Support Agreement with City of Hope effective July 8, 2024.","Agreement covered Phase 1b trial of LB-100 combined with Carboplatin/Etoposide/Atezolizumab for extensive-stage small cell lung cancer.","Company plans to explore alternative clinical trial sites to continue the study."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-027085","json":"https://secwatch.observer/filing/0001493152-24-027085.json","markdown":"https://secwatch.observer/filing/0001493152-24-027085.md","text":"https://secwatch.observer/filing/0001493152-24-027085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000149315224027085/0001493152-24-027085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000149315224027085/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T20:58:02.722207+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}